First National Advisers’s Jazz Pharmaceuticals JAZZ Stock Holding History

First National Advisers’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,440	Closed	-$2.54M	–	223
2025 Q1	$2.54M	Sell	20,440 -310	-1%	-$40.4K	0.41%	75
2024 Q4	$2.56M	Sell	20,750 -4,753	-19%	-$560K	0.41%	76
2024 Q3	$2.84M	Buy	25,503 +632	+3%	+$69.3K	0.45%	70
2024 Q2	$2.65M	Buy	24,871 +5,864	+31%	+$645K	0.49%	63
2024 Q1	$2.43M	Buy	19,007 +1,975	+12%	+$242K	0.54%	57
2023 Q4	$2.09M	Buy	17,032 +4,120	+32%	+$514K	0.6%	56
2023 Q3	$1.67M	Buy	12,912 +5,372	+71%	+$716K	0.75%	41
2023 Q2	$935K	Buy	7,540 +2,124	+39%	+$286K	0.86%	38
2023 Q1	$793K	Buy	+5,416	New	+$801K	0.9%	42

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

First National Advisers's JAZZ Position: Q2 2025 in Review

First National Advisers sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2025, closing a stake of 20,440 shares — an estimated $2.54M sold.

First National Advisers first reported a position in JAZZ in Q1 2023 and held it in 9 quarters. The position peaked at $2.84M in Q3 2024. 501 funds tracked by Wall St. Rank hold JAZZ as of Q2 2025.

First National Advisers reported no remaining Jazz Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
First National Advisers sold 20,440 Jazz Pharmaceuticals shares in Q2 2025, an estimated $2.54M.
First National Advisers first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 9 quarters.
First National Advisers's Jazz Pharmaceuticals position peaked at $2.84M in Q3 2024.
501 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2025.

Based on First National Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.